Drug
Catridecacog clinical trials
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2003 (3)
| Year | Studies |
|---|---|
| 2003 | 3 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 2
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Studies
Open first, then newest update. How each study uses catridecacog is read from its arms, and is right about nine times in ten.
Testing it · 12
- Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725CompletedPhase 3Novo Nordisk A/SNCT00978380Written as catridecacog
- Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart SurgeryCompletedPhase 2Novo Nordisk A/SNCT00914589Written as catridecacog
- Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited DeficiencyCompletedPhase 3Novo Nordisk A/SNCT00713648Written as catridecacog
- Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit DeficiencyCompletedPhase 3Novo Nordisk A/SNCT01230021Written as catridecacog
- Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll DeficiencyCompletedPhase 1Novo Nordisk A/SNCT00056589Written as catridecacog
- Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy VolunteersCompletedPhase 1Novo Nordisk A/SNCT01847989Written as catridecacog
- Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary BypassCompletedPhase 1Novo Nordisk A/SNCT02239146Written as catridecacog
- Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male SubjectsCompletedPhase 1Novo Nordisk A/SNCT01082406Written as catridecacog
- Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit DeficiencyCompletedPhase 3Novo Nordisk A/SNCT01253811Written as catridecacog
- A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative ColitisTerminatedPhase 2Novo Nordisk A/SNCT01706159Written as catridecacog
- Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese VolunteersCompletedPhase 1Novo Nordisk A/SNCT01153997Written as catridecacog
- Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy VolunteersCompletedPhase 1Novo Nordisk A/SNCT01848002Written as catridecacog
Codes
What other systems call catridecacog · ClinicalTrials.gg INT017410
- UNII (FDA) NU23Q531G1CATRIDECACOGConfirmed FDA, Wikidata
- RxNorm 1488293Confirmed FDA, Wikidata
- Wikidata Q16858452catridecacogConfirmed FDA, Wikidata
- NCI Thesaurus C174766CatridecacogOne source FDA
- DrugBank DB09310One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NU23Q531G1 | CATRIDECACOG | Confirmed FDA, Wikidata |
| RxNorm | 1488293 | — | Confirmed FDA, Wikidata |
| Wikidata | Q16858452 | catridecacog | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174766 | Catridecacog | One source FDA |
| DrugBank | DB09310 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.